Literature DB >> 1673932

Prevalence of HIV infection in 646 heroin addicts and outcome of HIV-related conditions in the 266 followed up.

C Mandelli1, D Conte, R Barbera, T Masullo, S Pistoso, G P Aimo, L Cesarini, M Fraguelli, G P Lorini, P A Bianchi.   

Abstract

In a series of 646 heroin addicts anti-HIV was detected in 428 (66.2%) and HBsAg in 53 (8.2%). Forty-eight (90.5%) of the latter had concomitant chronic HDV infection. Markers of past HBV infection were found in 481 (74.4%). The prevalence of anti-HIV was significantly higher in the 534 subjects with HBV markers than in the other 112 without markers (69.8% versus 49.1%, p less than 0.001). Of the 266 anti-HIV positive subjects followed for 3-48 months (median 12), nine progressed from no disease to persistent generalized lymphadenopathy (PGL), 52 from PGL to AIDS-related complex (ARC) or AIDS (30 and 22 cases respectively), and six from ARC to AIDS. Baseline T4 + cell count was significantly lower and reduction during follow-up significantly greater in heroin addicts with disease progression than in those without.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1673932     DOI: 10.1007/bf00221346

Source DB:  PubMed          Journal:  Eur J Epidemiol        ISSN: 0393-2990            Impact factor:   8.082


  21 in total

1.  Predictors of the acquired immunodeficiency syndrome developing in a cohort of seropositive homosexual men.

Authors:  B F Polk; R Fox; R Brookmeyer; S Kanchanaraksa; R Kaslow; B Visscher; C Rinaldo; J Phair
Journal:  N Engl J Med       Date:  1987-01-08       Impact factor: 91.245

2.  The Walter Reed staging classification for HTLV-III/LAV infection.

Authors:  R R Redfield; D C Wright; E C Tramont
Journal:  N Engl J Med       Date:  1986-01-09       Impact factor: 91.245

3.  HIV-1 infection among intravenous drug users in Manhattan, New York City, from 1977 through 1987.

Authors:  D C Des Jarlais; S R Friedman; D M Novick; J L Sotheran; P Thomas; S R Yancovitz; D Mildvan; J Weber; M J Kreek; R Maslansky
Journal:  JAMA       Date:  1989-02-17       Impact factor: 56.272

4.  Rapid spread of HTLV-III infection among drug addicts in Italy.

Authors:  G Angarano; G Pastore; L Monno; T Santantonio; N Luchena; O Schiraldi
Journal:  Lancet       Date:  1985-12-07       Impact factor: 79.321

5.  HTLV-III antibody in drug abusers in the west of Scotland: the Edinburgh connection.

Authors:  E A Follett; A McIntyre; B O'Donnell; G B Clements; U Desselberger
Journal:  Lancet       Date:  1986-02-22       Impact factor: 79.321

6.  A prospective study of human immunodeficiency virus type 1 infection and the development of AIDS in subjects with hemophilia.

Authors:  J J Goedert; C M Kessler; L M Aledort; R J Biggar; W A Andes; G C White; J E Drummond; K Vaidya; D L Mann; M E Eyster
Journal:  N Engl J Med       Date:  1989-10-26       Impact factor: 91.245

7.  Prevalence of antibodies to HTLV-I, -II, and -III in intravenous drug abusers from an AIDS endemic region.

Authors:  M Robert-Guroff; S H Weiss; J A Giron; A M Jennings; H M Ginzburg; I B Margolis; W A Blattner; R C Gallo
Journal:  JAMA       Date:  1986-06-13       Impact factor: 56.272

8.  Three-year incidence of AIDS in five cohorts of HTLV-III-infected risk group members.

Authors:  J J Goedert; R J Biggar; S H Weiss; M E Eyster; M Melbye; S Wilson; H M Ginzburg; R J Grossman; R A DiGioia; W C Sanchez
Journal:  Science       Date:  1986-02-28       Impact factor: 47.728

9.  The time from infection with human immunodeficiency virus (HIV) to the onset of AIDS.

Authors:  J M Taylor; K Schwartz; R Detels
Journal:  J Infect Dis       Date:  1986-10       Impact factor: 5.226

10.  Risk factors for human immunodeficiency virus infection in intravenous drug users.

Authors:  E E Schoenbaum; D Hartel; P A Selwyn; R S Klein; K Davenny; M Rogers; C Feiner; G Friedland
Journal:  N Engl J Med       Date:  1989-09-28       Impact factor: 91.245

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.